Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,134 JPY | +0.78% | -0.60% | +1.97% |
May. 16 | Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment | MT |
May. 15 | Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company appears to be poorly valued given its net asset value.
- This company will be of major interest to investors in search of a high dividend stock.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- One of the major weak points of the company is its financial situation.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 47.22 times its estimated earnings per share for the ongoing year.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.97% | 41.12B | B+ | ||
+40.15% | 723B | C+ | ||
+34.28% | 595B | B | ||
-3.74% | 369B | C+ | ||
+20.42% | 332B | B- | ||
+2.94% | 282B | C+ | ||
+17.02% | 244B | B+ | ||
+9.31% | 208B | B- | ||
-5.07% | 205B | A+ | ||
+0.36% | 168B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4502 Stock
- Ratings Takeda Pharmaceutical Company Limited